Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 60.40 kDa 
• Atom Count: 3862 
• Residue Count: 445 
• Unique protein chains: 1

2H8H

Src kinase in complex with a quinazoline inhibitor

• DOI: 10.2210/pdb2H8H/pdb

• Classification: TRANSFERASE
• Organism(s): Homo sapiens
• Expression System: Spodoptera frugiperda
• Mutation(s): No 


• Deposited: 2006-06-07 Released: 2006-11-21 
• Deposition Author(s): Otterbein, L.R., Norman, R., Pauptit, R.A., Rowsell, S., Breed, J.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.20 Å
• R-Value Free: 0.272 
• R-Value Work: 0.204 
• R-Value Observed: 0.207 

Literature

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.

Hennequin, L.F., Allen, J., Breed, J., Curwen, J., Fennell, M., Green, T.P., Lambert-van der Brempt, C., Morgentin, R., Norman, R.A., Olivier, A., Otterbein, L., Ple, P.A., Warin, N., Costello, G.

(2006) J Med Chem 49: 6465-6488

• PubMed: 17064066 
• DOI: 10.1021/jm060434q
• Primary Citation of Related Structures:  
  2H8H


• PubMed Abstract: 
  

Src family kinases (SFKs) are nonreceptor tyrosine kinases that are reported to be critical for cancer progression. We report here a novel subseries of C-5-substituted anilinoquinazolines that display high affinity and specificity for the tyrosine kinase domain of the c-Src and Abl enzymes. These compounds exhibit high selectivity for SFKs over a panel of recombinant protein kinases, excellent pharmacokinetics, and in vivo activity following oral dosing. N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine (AZD0530) inhibits c-Src and Abl enzymes at low nanomolar concentrations and is highly selective over a range of kinases. AZD0530 displays excellent pharmacokinetic parameters in animal preclinically and in man (t(1/2) = 40 h). AZD0530 is a potent inhibitor of tumor growth in a c-Src-transfected 3T3-fibroblast xenograft model in vivo and led to a significant increase in survival in a highly aggressive, orthotopic model of human pancreatic cancer when dosed orally once daily. AZD0530 is currently undergoing clinical evaluation in man.

---

Organizational Affiliation: 

Centre de Recherches, AstraZeneca, ZISE La Pompelle, B.P. 1050, 51689 Reims Cedex 2, France. [e-mail]

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Proto-oncogene tyrosine-protein kinase Src	A	535	Homo sapiens	Mutation(s): 0  Gene Names: SRC, SRC1 EC: 2.7.10.2
Find proteins for P12931 (Homo sapiens) Explore P12931  Go to UniProtKB:  P12931
NIH Common Fund Data Resources
PHAROS  P12931 GTEx  ENSG00000197122

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
H8H	A	N-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-7-[2-(4-METHYLPIPERAZIN-1-YL)ETHOXY]-5-(TETRAHYDRO-2H-PYRAN-4-YLOXY)QUINAZOLIN-4-AMINE C27 H32 Cl N5 O5 OUKYUETWWIPKQR-UHFFFAOYSA-N

Modified Residues  1 Unique
ID	Chains	Type	Formula	2D Diagram	Parent
PTR	A	L-PEPTIDE LINKING	C9 H12 N O6 P		TYR

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
H8H	IC50:  10   nM  BindingDB
H8H	IC50:  2.700000047683716   nM  Binding MOAD
H8H	IC50:  3   nM  BindingDB
H8H	IC50:  2.700000047683716   nM  BindingDB
H8H	IC50 :  2.700000047683716   nM  PDBBind
H8H	IC50:  1   nM  BindingDB

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.20 Å
• R-Value Free: 0.272 
• R-Value Work: 0.204 
• R-Value Observed: 0.207 
• Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 49.806	α = 90
b = 72.467	β = 90
c = 171.566	γ = 90

Software Package:

Software Name	Purpose
REFMAC	refinement
ADSC	data collection
MOSFLM	data reduction
AMoRE	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2006-06-07 
• Released Date: 2006-11-21 
Deposition Author(s): Otterbein, L.R., Norman, R., Pauptit, R.A., Rowsell, S., Breed, J.

Revision History 

• Version 1.0: 2006-11-21
  Type: Initial release
  
• Version 1.1: 2007-10-16
  Changes: Version format compliance
• Version 1.2: 2011-07-13
  Changes: Advisory, Derived calculations, Version format compliance
• Version 1.3: 2015-07-01
  Changes: Non-polymer description